Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 2.99B +148.5% |
| Revenue (ttm) | n/a |
| Net Income | -105.93M |
| EPS | -1.67 |
| Shares Out | 73.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,933 |
| Open | 40.85 |
| Previous Close | 40.98 |
| Day's Range | 40.58 - 41.21 |
| 52-Week Range | 14.79 - 62.32 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 73.67 (+80.48%) |
| Est. Earnings | Nov 11, 2026 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $73.67, which is an increase of 80.48% from the latest price.
News
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Enliven reaches alignment with FDA on final design of ENABLE-2 pivotal trial
Enliven (ELVN) Therapeutics announced that it has reached alignment with the U.S. FDA on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib in patients…
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage...
Enliven initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Enliven (ELVN) with an Overweight rating and $70 price target Enliven is a clinical-stage precision oncology company developing selective small-molecule kinase inh...
Enliven initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Enliven (ELVN) with an Overweight rating and $75 price target The company’s ELVN-001 can first address second-line post-allosteric chronic myeloid leukemia patients and ...
Enliven Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
ELVN-001 is positioned for strong differentiation in CML through superior efficacy, tolerability, and convenience, targeting both frontline and later-line settings. The company is well-capitalized to advance pivotal trials and expand into Graves' disease, with a $16 billion global market opportunity and a focus on regulatory execution and strategic pipeline growth.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven price target raised to $73 from $62 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Enliven (ELVN) to $73 from $62 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Enliven initiated with an Outperform at William Blair
William Blair initiated coverage of Enliven (ELVN) with an Outperform rating. The company is advancing ELVN-001, a “highly selective and efficacious” tyrosine kinase inhibitor for chronic myeloid leuk...
Enliven initiated with an Overweight at Barclays
Barclays analyst Etzer Darout initiated coverage of Enliven (ELVN) with an Overweight rating and $78 price target The company’s ELVN-001 has a “best-in-class” active site tyrosine kinase inhibitor in ...
Enliven price target raised to $75 from $60 at Baird
Baird raised the firm’s price target on Enliven (ELVN) to $75 from $60 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which…
Enliven price target raised to $82 from $80 at Stifel
Stifel analyst Dara Azar raised the firm’s price target on Enliven (ELVN) to $82 from $80 and keeps a Buy rating on the shares.
Enliven price target lowered to $78 from $80 at Guggenheim
Guggenheim lowered the firm’s price target on Enliven (ELVN) to $78 from $80 and keeps a Buy rating on the shares after the company reported Q2 results and provided a…
Enliven price target raised to $80 from $67 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Enliven (ELVN) to $80 from $67 and keeps a Buy rating on the shares.
Enliven price target raised to $68 from $55 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Enliven (ELVN) to $68 from $55 and keeps a Buy rating on the shares. Enliven remains on track to…
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key Ph...
Enliven Therapeutics Quarterly report: Q2 2026
Enliven Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Enliven Therapeutics Earnings release: Q2 2026
Enliven Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Enliven price target raised to $67 from $59 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Enliven (ELVN) to $67 from $59 and keeps a Buy rating on the shares.
Enliven price target raised to $65 from $56 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Enliven (ELVN) to $65 from $56 and keeps a Buy rating on the shares after raising the firm’s view…
Enliven price target raised to $80 from $60 at Stifel
Stifel raised the firm’s price target on Enliven (ELVN) to $80 from $60 and keeps a Buy rating on the shares. The firm is “more bullish” on its second-line and…
Enliven price target raised to $70 from $45 at JonesResearch
JonesResearch raised the firm’s price target on Enliven (ELVN) to $70 from $45 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect its…
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Why Is Enliven Therapeutics Stock (ELVN) Up Today?
Enliven Therapeutics stock was up on news of an upsized public offering.